---
layout: default
title: Aluminum Oxide
parent: Model Prediction Only (L5)
nav_order: 280
evidence_level: L5
indication_count: 10
---

# Aluminum Oxide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Aluminum Oxide: From No Labeled Indication to Rheumatoid Arthritis

## One-Sentence Summary

Aluminum oxide (alumina) has no approved indication in the available US regulatory data. It is marketed in pellet-form "Alumina" products.
The TxGNN model predicts it may be effective for **Rheumatoid Arthritis** with a very high score, but the **1 registered clinical trial** is an unrelated hip-implant device study, and none of the **20 publications** tests alumina as a treatment for the disease.
This is a model-only prediction with no supporting clinical evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 listings (no application numbers provided) |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Aluminum oxide is an inert ceramic material, an adsorbent and a vaccine adjuvant. It has no known anti-inflammatory or DMARD-like activity, so no credible therapeutic mechanism for rheumatoid arthritis can be identified.

The very high TxGNN score (99.98%) comes from the knowledge graph alone. The papers linked to this prediction fall into three groups: nanocarrier studies where the material is only a delivery scaffold, diagnostic assays that use kaolin or bentonite as reagents, and joint-implant studies where alumina is the bearing material. None of them treats rheumatoid arthritis with alumina.

The other nine top-ranked predictions (for example brachydactyly-syndactyly syndrome, heparin cofactor 2 deficiency and thrombotic disease) also lack clinical support.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT00764530](https://clinicaltrials.gov/study/NCT00764530) | Not applicable (device) | Completed | 342 | Ceramic-on-ceramic total hip system with an alumina insert and head. It tests implant safety and performance, not rheumatoid arthritis treatment (relevance grade C). |

---

## Literature Evidence

No RCTs were found. The table lists the most relevant items, ordered roughly by closeness to the topic.

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [12211691](https://pubmed.ncbi.nlm.nih.gov/12211691/) | 2002 | In vitro | J Bone Joint Surg Br | Alumina and zirconia particles were tested on synoviocytes from osteoarthritis and RA patients for IL-1, IL-6 and arachidonic acid metabolism. This is a biomaterial safety model, not a treatment study, and the abstract indicates no significant effect. |
| [2838005](https://pubmed.ncbi.nlm.nih.gov/2838005/) | 1988 | Review | Arch Pathol Lab Med | Silica-related disease review that lists rheumatoid arthritis as a possible complication of exposure. This suggests risk, not benefit. |
| [30062938](https://pubmed.ncbi.nlm.nih.gov/30062938/) | 2018 | Clinical study | Bone Joint J | Mid-term outcomes of alumina ceramic elbow replacement in RA patients. The alumina is an implant material, not a drug. |
| [28238009](https://pubmed.ncbi.nlm.nih.gov/28238009/) | 2017 | Case series | Acta Med Okayama | Long-term results of cementless alumina ceramic elbow replacement in 17 RA patients. This is again about implants. |
| [16882533](https://pubmed.ncbi.nlm.nih.gov/16882533/) | 2006 | Case-control | Environ Health Perspect | Asbestos exposure and autoimmune disease risk in Libby, Montana. It is unrelated to alumina treatment. |
| [35549591](https://pubmed.ncbi.nlm.nih.gov/35549591/) | 2022 | Preclinical | J Drug Target | ZIF-8 nanoparticles for targeted dexamethasone delivery to arthritic joints. The active drug is dexamethasone, not alumina. |
| [35819069](https://pubmed.ncbi.nlm.nih.gov/35819069/) | 2022 | Preclinical | ACS Biomater Sci Eng | CeO2-ZIF-8 nanocomposite for photothermal and ROS-scavenging RA therapy. It does not involve alumina. |
| [22193222](https://pubmed.ncbi.nlm.nih.gov/22193222/) | 2012 | Animal study | Rheumatol Int | Kaolin/carrageenan-induced arthritis was more severe in older rats. Kaolin is used here to induce arthritis, not to treat it. |
| [32707885](https://pubmed.ncbi.nlm.nih.gov/32707885/) | 2020 | Preclinical | Molecules | A benzylideneacetophenone derivative was tested in a kaolin/carrageenan arthritis rat model. Kaolin is only the inducing agent. |
| [32342135](https://pubmed.ncbi.nlm.nih.gov/32342135/) | 2020 | Preclinical | Naunyn Schmiedebergs Arch Pharmacol | Malva parviflora extract was tested in a kaolin/carrageenan mono-arthritis mouse model. It is unrelated to alumina therapy. |

---

## US Market Information

The 20 listings appear to be "Alumina" pellet products from homeopathic-style manufacturers (Boiron and Hahnemann Laboratories). The source data gives no license numbers or approved indication text. The first 5 listings are shown.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| Not provided | Alumina (Boiron) | Pellet | Not stated |
| Not provided | Alumina (Hahnemann Laboratories, Inc.) | Pellet | Not stated |
| Not provided | Alumina (Hahnemann Laboratories, Inc.) | Pellet | Not stated |
| Not provided | Alumina (Boiron) | Pellet | Not stated |
| Not provided | Alumina (Hahnemann Laboratories, Inc.) | Pellet | Not stated |

Other dosage forms in the data are globules and liquids.

---

## Safety Considerations

Please refer to the package insert for safety information.

No drug interactions were found in the queried data.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on the knowledge graph alone. The one registered trial is an implant device study, and the literature contains no test of alumina as a rheumatoid arthritis therapy. No plausible mechanism exists, and the safety data required for screening is missing.

**To proceed, the following is needed:**
- FDA package insert warnings and contraindications (blocking gap; safety screening cannot start without them)
- Mechanism of action data from DrugBank
- A plausible anti-inflammatory or immunomodulatory mechanism for alumina, backed by preclinical evidence
- Confirmation of whether the marketed products carry any labeled indication
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

